

### 3.0 INFORMED CONSENT AND REFUSAL OF CONSENT

<b>Policy</b>	<ul style="list-style-type: none"> <li>• Procedures for the administration blood components and products shall include a mechanism for obtaining informed consent</li> <li>• Elements of informed consent include discussion of:             <ul style="list-style-type: none"> <li>» A description of the blood component(s) and /or product(s) which may be transfused</li> <li>» The risks of such transfusion</li> <li>» The expected benefits of such transfusion</li> <li>» Possible alternatives to transfusion and the risks and benefits of such alternatives</li> <li>» The patient must be given the opportunity to ask questions and have concerns addressed</li> <li>» The clinical indication for transfusion shall be recorded in the patient’s medical record</li> </ul> </li> <li>• In the case of planned elective transfusion, this discussion should take place well in advance of the planned procedure or course of treatment to allow for the application of possible alternatives</li> <li>• Evidence of acceptance or refusal of informed consent for the transfusion of blood components or products shall be recorded in the patient’s medical record, whether written or electronic</li> </ul>
<b>Reason</b>	<ul style="list-style-type: none"> <li>• Informed consent is a process undertaken jointly by a patient (or substitute decision maker where required) and a physician to make a therapeutic decision in a manner that preserves the patient’s primary decision-making role in determining a course of treatment</li> <li>• Obtaining consent for medical treatment in general is a principle of common law (Ontario Consent to Treatment Act, 1996)</li> <li>• Consent specifically for transfusion of blood components and products, while not expressly required by law in Ontario, is a requirement of the standards published by the CSA, CSTM and IQMH</li> </ul>
<b>Patient population</b>	<ul style="list-style-type: none"> <li>• All patients for whom transfusion is indicated or may be indicated</li> <li>• In circumstances where consent cannot be obtained (e.g. under anaesthesia or trauma)</li> </ul>
<b>Responsibilities of Medical Director, Transfusion Medicine</b>	<p>Provide information, promote education for and consult with all health professionals involved in the transfusion process about:</p> <ul style="list-style-type: none"> <li>• The risks and benefits of transfusion of blood components and products</li> <li>• The appropriate use of blood components and products</li> <li>• Alternatives to transfusion</li> </ul>
<b>Responsibilities of Treating physician</b>	<ul style="list-style-type: none"> <li>• Obtain consent for or refusal of transfusion and document in the patient’s medical record</li> <li>• Complete the facility specific form for consent or refusal if applicable</li> </ul>
<b>Responsibilities of Treating nurse</b>	<ul style="list-style-type: none"> <li>• Confirm that consent has been recorded in the patient’s medical record before requesting product from the Transfusion Medicine Service</li> <li>• Inform or send a record of refusal (if applicable) of transfusion to the Transfusion Medicine Service for entry in its record system</li> </ul>
<b>Responsibilities of Transfusion Medicine Staff</b>	<ul style="list-style-type: none"> <li>• Record refusal of consent to transfusion in Transfusion Medicine Service patient information file on receipt of notification of refusal</li> <li>• Check patient history in Transfusion Medicine Service information file on receipt of request for component or product</li> <li>• Notify Medical Director, Transfusion Medicine when blood component or product is requested for a patient for whom a record of refusal of consent is on record</li> </ul>



**Refusal of consent**

- The discussion and refusal of consent shall be recorded in the patient's medical record
- The Transfusion Medicine Service should have a notation of the refusal of consent in its patient information file, as a secondary check to prevent release of blood component or product that is ordered erroneously

**REFERENCES**

1. AABB, 2006.
17. Bodnaruk ZM, 2004.
25. Callum JL, 2016.
29. CSTM, Informed Consent-Position paper.
43. Davis RE, 2011.
52. Farrell AM, 2010.
63. Krever, H, 1997.
64. BC PBCO, 1999.
69. IQMH, 2018.
80. Lima A, 2015.

